Bold statement: The landscape of heart failure in the United States is changing in ways that challenge old assumptions and demand new strategies. And this is the part most people miss: the rise in HF burden over the past 35 years appears less tied to traditional ischemic culprits and more linked to metabolic and kidney-related factors. Here’s what the latest analysis, grounded in NHANES data, is telling us and why it matters for patients, researchers, and policymakers.
New insights from NHANES
A study published online in JACC analyzed data from 83,552 ambulatory adults (median age 45; 52% women), with 3,078 reporting a history of heart failure. Between 1988 and 2023, the crude HF prevalence increased from 2.1% to 3.0%—a 43% relative rise. However, when broken down by age, HF prevalence did not change over time, suggesting that age remains a stronger driver of who develops HF than the time period itself.
Shifts in risk factors among HF patients
Among those with HF, obesity rose markedly—from 32.5% in 1988 to 60.4% in 2023. Impaired glucose homeostasis climbed from 48.6% to 69.2%, diabetes from 21.2% to 36.2%, and chronic kidney disease from 38.6% to 52.3%. In contrast, the proportions with elevated blood pressure dropped from 80.7% to 49.1%, hypercholesterolemia from 71.5% to 22.6%, and prior myocardial infarction from 59.3% to 42.1%. These patterns illustrate a decisive shift from traditional ischemic drivers toward metabolic and renal factors as HF contributors.
Therapeutic and lifestyle changes accompany trends
Over the study period, use of several cornerstone HF therapies rose: ACE inhibitors/ARBs from 9.2% to 54.7%, beta-blockers from 6.2% to 71.7%, and statins from 5.3% to 72.7%. Smoking rates declined from 34.8% to 16.4%. These treatment and lifestyle changes likely reflect broader improvements in preventive cardiology and chronic disease management.
Mortality and quality of life outcomes
Both HF patients and those without HF saw reductions in cardiovascular mortality over time (hazard ratio for mortality among HF patients: 0.30; 95% CI 0.22–0.41; and for those without HF: 0.41; 95% CI 0.34–0.48). Self-reported health status and physical function improved in HF patients, though work-related impairment did not show the same improvement. This pattern hints at better overall health management and symptom control, even as the population with HF grows in prevalence.
Caveats and alternate interpretations
Commentators note notable limitations, chiefly the reliance on self-reported data and gaps in medication adherence and lab data within NHANES. These constraints mean the findings should be interpreted with caution. Nevertheless, the editors highlight a clear trend toward a metabolic-and-kidney–driven HF profile and urge the field to rethink how trials are designed and whom they include.
Implications for research and trials
The editorialists argue that these results justify a shift in research focus toward metabolism-, kidney-, and aging-related mechanisms of ventricular remodeling and disease progression. They specifically advocate for trials that address obesity as a modifiable driver in HF with reduced ejection fraction, given its association with adverse outcomes, functional impairment, and multimorbidity.
Additionally, they stress exploring how biological aging processes and physical frailty affect the heart, and call for more inclusive trial designs that do not exclude participants with high BMI or advanced CKD. Prevention of HF—through risk factor modification and early intervention—should also be prioritized as part of comprehensive care strategies.
A holistic view for the future
Taken together, these findings point to a rapidly evolving HF landscape that requires parallel evolution in trial concepts, designs, and execution. HF is not an inevitability, and the cardiovascular community bears the responsibility to demonstrate that preventable progress is possible.
Controversial notes and questions for readers
- Do these data justify prioritizing metabolic and renal targets over classic ischemic strategies in HF prevention and treatment?
- How should clinical trials be redesigned to ensure diverse patient populations (including those with obesity and advanced CKD) are adequately represented?
- With the pandemic era underway, what additional shifts might have occurred in HF prevalence and outcomes beyond 2023, and how should ongoing studies account for these influences?
What’s your take? Do you see the shift toward metabolic and kidney drivers as a call to change clinical practice, or do traditional ischemic approaches still hold primary importance in HF management? Share your perspective in the comments.
